Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) EBT Margin (2016 - 2025)

Historic EBT Margin for Sunshine Biopharma (SBFM) over the last 9 years, with Q3 2025 value amounting to 10.84%.

  • Sunshine Biopharma's EBT Margin rose 8000.0% to 10.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.44%, marking a year-over-year decrease of 49600.0%. This contributed to the annual value of 15.4% for FY2024, which is 16700.0% up from last year.
  • Per Sunshine Biopharma's latest filing, its EBT Margin stood at 10.84% for Q3 2025, which was up 8000.0% from 21.04% recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's EBT Margin ranged from a high of 783.75% in Q4 2021 and a low of 15440.43% during Q1 2021
  • Its 5-year average for EBT Margin is 1650.19%, with a median of 21.04% in 2025.
  • As far as peak fluctuations go, Sunshine Biopharma's EBT Margin crashed by -145914000bps in 2021, and later skyrocketed by 144324500bps in 2022.
  • Sunshine Biopharma's EBT Margin (Quarter) stood at 783.75% in 2021, then crashed by -175bps to 590.86% in 2022, then soared by 98bps to 13.41% in 2023, then plummeted by -78bps to 23.83% in 2024, then skyrocketed by 55bps to 10.84% in 2025.
  • Its EBT Margin stands at 10.84% for Q3 2025, versus 21.04% for Q2 2025 and 13.71% for Q1 2025.